European Hematology Association - Daratumumab Maintenance Improves Progression-Free Survival After Autologous Stem Cell Transplantation in Multiple Myeloma Patients
- S&P 500 edges down on virus woes, slowing economy
- 'Becoming JP Morgan of the Future': Square (SQ) Dips on Deal to Acquire BNPL Afterpay For $29B in Stock, Benefits Outweigh High Price Says Analyst
- Oil falls over 3% on concerns over demand and OPEC supply boost
- ON Semiconductor (ON) Surges on Strong Q2 Results and Q3 Outlook
- Dollar wavers on dovish Fed tone, mixed economic outlook
Get instant alerts when news breaks on your stocks. Claim your 1-week free trial to StreetInsider Premium here.
THE HAGUE, Netherlands, June 12, 2021 /PRNewswire/ -- Part 1 of the CASSIOPEIA phase-3 study compared the addition of daratumumab to bortezomib, thalidomide, and dexamethasone (D-VTd) induction/consolidation with VTd alone in transplant-eligible patients with newly diagnosed multiple myeloma. The results of the study showed superior efficacy of D-VTd over VTd alone in combination with autologous stem cell transplantation (ASCT), which led to the regulatory approval of the treatment. Here, we present the results from the CASSIOPEIA part 2 interim analysis aimed to compare daratumumab maintenance (16 mg/kg every 8 weeks) with observation treatment in all 886 responders from part 1 of the study.
Our interim analysis showed that patients maintained with daratumumab exhibited significantly longer progression-free survival (PFS) compared to the observation treatment arm. However, stratification of the patients by induction/consolidation treatment revealed that this benefit only appeared in patients previously treated with VTd in CASSIOPEIA part 1. Patients who received D-VTd in part 1 and were placed on daratumumab maintenance showed comparable PFS to the observation group. Furthermore, daratumumab maintenance led to a significantly higher depth of response and no new safety signals were detected. In summary, daratumumab maintenance is beneficial for patients after ASCT who received VTd induction/consolidation.
Presenter: Professor Phillipe Moreau
Affiliation: CHU de Nantes, Nantes, France
Abstract: #S180 DARATUMUMAB MAINTENANCE VS OBSERVATION IN PATIENTS WITH NEWLY DIAGNOSED MULTIPLE MYELOMA TREATED WITH BORTEZOMIB, THALIDOMIDE, AND DEXAMETHASONE ± DARATUMUMAB AND ASCT: CASSIOPEIA PART 2 RESULTS
About the EHA Annual Congress: Every June, EHA organizes its Annual Congress in a major European city. This year, due to the persisting COVID19 pandemic, EHA organizes a virtual Congress for the second time. The Congress is aimed at health professionals working in or interested in the field of hematology. The scientific program topics range from stem cell physiology and development to leukemia; lymphoma; diagnosis and treatment; red blood cells; white blood cells and platelet disorders; hemophilia and myeloma; thrombosis and bleeding disorders; as well as transfusion and stem cell transplantation.
View original content to download multimedia:http://www.prnewswire.com/news-releases/european-hematology-association---daratumumab-maintenance-improves-progression-free-survival-after-autologous-stem-cell-transplantation-in-multiple-myeloma-patients-301308008.html
SOURCE European Hematology Association (EHA)
Serious News for Serious Traders! Try StreetInsider.com Premium Free!
You May Also Be Interested In
- JetRails Announces Magento Hosting Rescue Service
- Spin Master Entertainment, Paramount Pictures and Nickelodeon Announce Singer-Songwriter Alessia Cara to Perform New Original Song for the Upcoming PAW Patrol: The Movie™
- Arcis Golf Acquires Arizona-based Mickelson Golf Properties
Create E-mail Alert Related CategoriesPRNewswire, Press Releases
Sign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!